At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 28 enrolled
Drug / intervention
carnitine +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Carnitine Supplementation and Skeletal Muscle Function in Aging
Gdansk University of Physical Education and Sport·interventional·Posted Feb 26, 2016·Updated May 23, 2019
In Brief
A Phase 3 clinical trial evaluating carnitine and placebo for Sarcopenia. Completed, enrolled 28 participants across 1 site.
Detailed Summary
Research project objectives The primary aim of the current research project is to use carnitine supplementation as the anti-inflammatory intervention for exploring the relationship between inflammation and associated with aging reduction of skeletal muscle mass. Hypothesis The carnitine supplementation modulates the blood cytokines concentration. Anti-inflammatory intervention delay the reduction of skeletal muscle mass associated with aging
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia
CountriesPoland
CollaboratorsNational Science Centre, Poland
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionMar 2017
Study CompletionJul 2017
TodayJul 2026
First PostedFeb 26, 2016
Enrollment StartFeb 1, 2016
Primary CompletionMar 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.3 years ago
Interventions
carnitinedietary
1500 mg/d l-carnitine-l-tartrate
placebodietary
isonitrogenous